Board Member
Relmada Therapeutics, Inc. (RLMD)Equibles does not estimate personal net worth.
Get an email with a short summary when Relmada Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get RLMD alertsSergio Traversa is recorded as CEO and Board Member at Relmada Therapeutics, Inc. (RLMD). The newest filing on record that lists Sergio Traversa as CEO and Board Member at Relmada Therapeutics, Inc. (RLMD) is dated April 17, 2026. Relmada Therapeutics, Inc. reported in an 8-K filed May 25, 2023 that Sergio Traversa was appointed Class II Director, effective May 25, 2023. Sergio Traversa has spoken on 22 earnings calls and 1 other investor event across 1 company, most recently for Relmada Therapeutics, Inc. on November 12, 2026. Relmada Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Relmada Therapeutics, Inc. includes Charles J. Casamento (Chairman and Board Member), Maged Shenouda (CFO), Paul Kelly (COO and Board Member) and 3 others.
“Stockholders elected the following nominees as directors to hold office until the 2026 Annual Meeting (i.e. as a Class II Director) and until his successor is elected and qualified.”
“We have made significant progress with the NDW-1 program in the third quarter, and during today's call, I will provide the business overview, including an update on manufacturing.”
“Well, thank you, Farzin, and thank you, the old Jeffries team, for inviting us. Good afternoon to everyone. and I'm Sergio Travers, I'm the co-founder and the CEO of RealMada.”
“Good afternoon, and welcome, everyone, to the RealMata first quarter 2026 conference call. RELMADA continues to make excellent progress this year, and we are excited about where we stand.”
“Good afternoon, and welcome, everyone, to the RELMADA fourth quarter and year-end 2025 conference call. 2025 has been a transformational year for RELMADA, marked by significant progress for our lead program, NDVO-1.”
“And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call.”
Start not stated–present
Last confirmed April 17, 2026
Start not stated–present
Last confirmed April 17, 2026
Biotechnology · Healthcare
CEO, Board Member
